342 related articles for article (PubMed ID: 9284737)
1. Mutation analysis of glial cell line-derived neurotrophic factor, a ligand for an RET/coreceptor complex, in multiple endocrine neoplasia type 2 and sporadic neuroendocrine tumors.
Marsh DJ; Zheng Z; Arnold A; Andrew SD; Learoyd D; Frilling A; Komminoth P; Neumann HP; Ponder BA; Rollins BJ; Shapiro GI; Robinson BG; Mulligan LM; Eng C
J Clin Endocrinol Metab; 1997 Sep; 82(9):3025-8. PubMed ID: 9284737
[TBL] [Abstract][Full Text] [Related]
2. Infrequent detectable somatic mutations of the RET and glial cell line-derived neurotrophic factor (GDNF) genes in human pituitary adenomas.
Yoshimoto K; Tanaka C; Moritani M; Shimizu E; Yamaoka T; Yamada S; Sano T; Itakura M
Endocr J; 1999 Feb; 46(1):199-207. PubMed ID: 10426588
[TBL] [Abstract][Full Text] [Related]
3. RET proto-oncogene mutations in multiple endocrine neoplasia type 2 and medullary thyroid carcinoma.
Marsh DJ; Mulligan LM; Eng C
Horm Res; 1997; 47(4-6):168-78. PubMed ID: 9167949
[TBL] [Abstract][Full Text] [Related]
4. Glial cell line-derived neurotrophic factor differentially stimulates ret mutants associated with the multiple endocrine neoplasia type 2 syndromes and Hirschsprung's disease.
Carlomagno F; Melillo RM; Visconti R; Salvatore G; De Vita G; Lupoli G; Yu Y; Jing S; Vecchio G; Fusco A; Santoro M
Endocrinology; 1998 Aug; 139(8):3613-9. PubMed ID: 9681515
[TBL] [Abstract][Full Text] [Related]
5. Rudolf-Virchow-Preis 1995. The role of RET proto-oncogene mutation analysis in the diagnosis of multiple endocrine neoplasia type 2 (MEN 2) gene carriers and in the discrimination of sporadic and familial medullary thyroid carcinomas and pheochromocytomas.
Komminoth P
Verh Dtsch Ges Pathol; 1995; 79():L-LV. PubMed ID: 8600671
[TBL] [Abstract][Full Text] [Related]
6. Co-segregation of MEN2 and Hirschsprung's disease: the same mutation of RET with both gain and loss-of-function?
Takahashi M; Iwashita T; Santoro M; Lyonnet S; Lenoir GM; Billaud M
Hum Mutat; 1999; 13(4):331-6. PubMed ID: 10220148
[TBL] [Abstract][Full Text] [Related]
7. Genetic predisposition to phaeochromocytoma: analysis of candidate genes GDNF, RET and VHL.
Woodward ER; Eng C; McMahon R; Voutilainen R; Affara NA; Ponder BA; Maher ER
Hum Mol Genet; 1997 Jul; 6(7):1051-6. PubMed ID: 9215674
[TBL] [Abstract][Full Text] [Related]
8. Investigation of the genes for RET and its ligand complex, GDNF/GFR alpha-I, in small cell lung carcinoma.
Mulligan LM; Timmer T; Ivanchuk SM; Campling BG; Young LC; Rabbitts PH; Sundaresan V; Hofstra RM; Eng C
Genes Chromosomes Cancer; 1998 Apr; 21(4):326-32. PubMed ID: 9559344
[TBL] [Abstract][Full Text] [Related]
9. Multiple endocrine neoplasia type 1 and 2: from morphology to molecular pathology 1997.
Komminoth P
Verh Dtsch Ges Pathol; 1997; 81():125-38. PubMed ID: 9474863
[TBL] [Abstract][Full Text] [Related]
10. Role of the RET proto-oncogene in sporadic hyperparathyroidism and in hyperparathyroidism of multiple endocrine neoplasia type 2.
Pausova Z; Soliman E; Amizuka N; Janicic N; Konrad EM; Arnold A; Goltzman D; Hendy GN
J Clin Endocrinol Metab; 1996 Jul; 81(7):2711-8. PubMed ID: 8675600
[TBL] [Abstract][Full Text] [Related]
11. Genetic analysis of RET, GFR alpha 1 and GDNF genes in Spanish families with multiple endocrine neoplasia type 2A.
Gil L; Azañedo M; Pollán M; Cristobal E; Arribas B; García-Albert L; García-Sáiz A; Maestro ML; Torres A; Menárguez J; Rojas JM
Int J Cancer; 2002 May; 99(2):299-304. PubMed ID: 11979448
[TBL] [Abstract][Full Text] [Related]
12. Mutations of the RET proto-oncogene in the multiple endocrine neoplasia type 2 syndromes, related sporadic tumours, and hirschsprung disease.
Eng C; Mulligan LM
Hum Mutat; 1997; 9(2):97-109. PubMed ID: 9067749
[TBL] [Abstract][Full Text] [Related]
13. Mutational analysis of the GDNF/RET-GDNFR alpha signaling complex in a kindred with vesicoureteral reflux.
Shefelbine SE; Khorana S; Schultz PN; Huang E; Thobe N; Hu ZJ; Fox GM; Jing S; Cote GJ; Gagel RF
Hum Genet; 1998 Apr; 102(4):474-8. PubMed ID: 9600247
[TBL] [Abstract][Full Text] [Related]
14. Mutation analysis of glial cell line-derived neurotrophic factor (GDNF), a ligand for the RET/GDNF receptor alpha complex, in sporadic phaeochromocytomas.
Dahia PL; Toledo SP; Mulligan LM; Maher ER; Grossman AB; Eng C
Cancer Res; 1997 Jan; 57(2):310-3. PubMed ID: 9000574
[TBL] [Abstract][Full Text] [Related]
15. Analysis of RET proto-oncogene abnormalities in patients with MEN 2A, MEN 2B, familial or sporadic medullary thyroid carcinoma.
Chiefari E; Russo D; Giuffrida D; Zampa GA; Meringolo D; Arturi F; Chiodini I; Bianchi D; Attard M; Trischitta V; Bruno R; Giannasio P; Pontecorvi A; Filetti S
J Endocrinol Invest; 1998 Jun; 21(6):358-64. PubMed ID: 9699127
[TBL] [Abstract][Full Text] [Related]
16. Distinction between sporadic and hereditary medullary thyroid carcinoma (MTC) by mutation analysis of the RET proto-oncogene. "Study Group Multiple Endocrine Neoplasia Austria (SMENA)".
Fink M; Weinhüsel A; Niederle B; Haas OA
Int J Cancer; 1996 Aug; 69(4):312-6. PubMed ID: 8797874
[TBL] [Abstract][Full Text] [Related]
17. Characterization of Ret-Shc-Grb2 complex induced by GDNF, MEN 2A, and MEN 2B mutations.
Ohiwa M; Murakami H; Iwashita T; Asai N; Iwata Y; Imai T; Funahashi H; Takagi H; Takahashi M
Biochem Biophys Res Commun; 1997 Aug; 237(3):747-51. PubMed ID: 9299438
[TBL] [Abstract][Full Text] [Related]
18. Expression analysis of RET and the GDNF/GFRalpha-1 and NTN/GFRalpha-2 ligand complexes in pheochromocytomas and paragangliomas.
Edström E; Frisk T; Farnebo F; Höög A; Bäckdahl M; Larsson C
Int J Mol Med; 2000 Oct; 6(4):469-74. PubMed ID: 10998441
[TBL] [Abstract][Full Text] [Related]
19. [Germline mutations of the ret proto-oncogene in Chilean patients with hereditary and sporadic medullary thyroid carcinoma].
Wohllk N; Becker P; Youlton R; Cote GJ; Gagel RF
Rev Med Chil; 2001 Jul; 129(7):713-8. PubMed ID: 11552438
[TBL] [Abstract][Full Text] [Related]
20. Expression of RET and its ligand complexes, GDNF/GFRalpha-1 and NTN/GFRalpha-2, in medullary thyroid carcinomas.
Frisk T; Farnebo F; Zedenius J; Grimelius L; Höög A; Wallin G; Larsson C
Eur J Endocrinol; 2000 Jun; 142(6):643-9. PubMed ID: 10822229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
